Trending News: Trial Supports Efficacy of FTAF for PrEP

Top news from across the health care landscape.

Newly presented data from the DISCOVER trial evaluating emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets (F/TAF) demonstrated continued non-inferior efficacy to emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (F/TDF) for pre-exposure prohphylaxis (PrEP), according to Contagion Live. Additionally, 96-week results indicate that compared with F/TDF, F/TAF had favorable changes in key markers of renal and bone safety among trial participants of various ages. F/TAF is a safe, long-term option for PrEP, with certain subgroups experiencing a greater magnitude of benefit in bone mineral density and renal biomarkers, according to the study authors.

Fall-related traumatic brain injury (TBI) deaths are increasing steadily in older populations, according to HCP Live. A new report by the CDC indicates that fall-related TBI deaths increased from 3.86 per 100,000 individuals in 2008 to 4.52 per 100,000 people in 2017, representing a 17% increase. Overall, there were 17,408 fall-related TBI deaths in 2017 and 12,311 deaths in 2008.

Patients with Parkinson disease (PD) were found to be more likely to experience vision and eye issues, such as blurry vision, dry eyes, trouble with depth perception, and problems adjusting to rapid changes in light compared with people without the disorder, according to The American Journal of Managed Care. Researchers aimed to determine the prevalence of a wide range of ophthalmologic symptoms in a large sample of patients with PD compared with controls to explore the effect of these ophthalmologic symptoms on daily life functioning. Screening within PD communities is important, since many of the vision and eye issues were potentially treatable, according to the study authors.